Biochemical and functional evaluation of the sympathectomy produced by the administration of guanethidine to newborn rats.
The administration of guanethidine to newborn rats has been shown by morphological criteria to destroy sympathetic neurons. Newborn rats were injected with guanethidine (50-100 mg/kg/day for 20 days). Upon maturation (at 10 weeks old), the degree of destruction of the sympathetic nervous system (sympathectomy) was assessed. Marked decreases (80-98%) in the norepinephrine concentration in several tissues (heart, spleen, intestine, mesentery, kidney, uterus, vas deferens) were observed in the guanethidine-treated rats when compared to saline-treated controls. No changes were observed in the epinephrine concentration in the adrenals or in the norepinephrine levels in whole brain. Analysis of brain areas showed no change in the norepinephrine levels in brain stem and cerebrum and a small (18%) decrease in the cerebellum. Stimulation of the sympathetic vasomotor outflow in the pithed rat preparation produced almost no response in guanethidine-treated animals. Periarterial nerve stimulation of the isolated perfused kidney preparation also produced essentially no response in guanethidine-treated animals. Isolated intestinal preparations from guanethidine-treated animals responded to nerve stimulation with contractions rather than relaxation as seen in preparations from control animals. Isolated vas deferens preparations responded normally to nerve stimulation despite a 95% decrease in tissue norepinephrine concentration. These data indicate that administration of guanethidine to newborn rats produces a more complete peripheral sympathectomy, especially of the vasculature, than immunosympathectomy or neonatal administration of 6-hydroxydopamine and does so with no significant effect on central noradrenergic neurons.
D000311:Adrenal Glands / Q000032:analysis; D000315:Adrenalectomy; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D001835:Body Weight / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D004837:Epinephrine / Q000032:analysis; D005260:Female; D005727:Ganglia, Spinal / Q000201:enzymology; D006145:Guanethidine / Q000494:pharmacology*; D006892:Hydroxydopamines / Q000494:pharmacology; D007422:Intestines / Q000032:analysis; D007668:Kidney / Q000032:analysis; D008297:Male; D009206:Myocardium / Q000032:analysis; D009638:Norepinephrine / Q000032:analysis; D011247:Pregnancy; D051381:Rats; D013116:Spinal Cord / Q000502:physiology; D013154:Spleen / Q000032:analysis; D013562:Sympathectomy; D013564:Sympathetic Nervous System / Q000502:physiology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D014599:Uterus / Q000032:analysis; D014649:Vas Deferens / Q000032:analysis
D006892:Hydroxydopamines; D014446:Tyrosine 3-Monooxygenase; D009638:Norepinephrine; D004837:Epinephrine; D006145:Guanethidine